Not for distribution to United States newswire services or for dissemination in the United States.
Hydreight Technologies, a North American, fully integrated, mobile clinical network of nurses, doctors, and pharmacy distribution, is pleased to announce that it has entered into a binding letter of intent dated September 5, 2025 (the “LOI”) with Auxano One LLC (“Auxano”), an arm’s length limited liability company based in Pennsylvania, in respect of a strategic asset acquisition and commercial relationship (the “Transaction”).
Pursuant to the LOI, the parties have agreed that:
- the Company would (a) acquire Auxano’s Dynamic IV Therapy Support AI Agent (the “Target Asset”) or (a) acquire the right to use the Target Asset (either, the “Target Asset Acquisition”);
- in exchange for the Target Asset Acquisition, Auxano will be entitled to the following consideration:
- on closing (the “Closing”) of the Transaction, the Company will pay to Auxano US $70,000 in cash,
- upon the occurrence of a business milestone whereby the Target Asset is fully functional, integrated into the VSDHOne Platform and Hydreight App, and operational for intended use, and deliverable upon approval by the Company, the Company will issue 120,000 common shares in the capital of the Company (each, a “Company Share”) to Auxano,
- upon the occurrence of a business milestone whereby US $5,000,000 in revenue is generated in the aggregate for the Company and/or the VSDHOne by the Target Asset, the Company will issue 55,000 Company Shares to Auxano, and
- Auxano will be entitled to certain revenue sharing rights in respect of the Target Asset as further described in the LOI; and
- the Company and Auxano will agree to a commercial relationship in respect of the Target Asset as further described in the LOI.
Read More: SalesTechStar Interview with Tim Baynes, Founder and CEO at Compatio
Shane Madden, CEO of Hydreight, commented: “We have been focused on developing and integrating artificial intelligence (AI) into our technologies across all three verticals, giving our customers powerful tools to create treatment plans for their patients. This not only enhances their ability to market services effectively but, more importantly, supports patients with long-term treatment planning. It’s an ideal addition to our ecosystem—tying together our pharmacies, technology platforms, and at-home testing solutions in a way that drives value for both providers and patients.”
Description of Target Asset
Dynamic IV Therapy Support AI Agent –An AI clinical assistant that analyzes patient health data (blood panels, genetic tests, health records) against standardized protocols to generate personalized IV therapy, supplements and preventative treatments recommendations.
- Processes uploaded reports and electronic medical records data to suggest optimal IV drip formulations, nutrient concentrations, and complementary oral supplementation protocols.
- Ensures recommendations align with established standard operating procedures while providing clinical rationale, including contraindications and monitoring parameters.
- Streamlines treatment planning for providers while maintaining safety and efficacy standards.
Expanded Use Cases and Vertical Integration
While initially focused on IV therapy, the AI agent has broader applications across the health and wellness spectrum. By analyzing patient data such as blood panels, genetic testing, and medical history, the assistant could be adapted to support:
- Hormone and longevity treatments – optimizing personalized protocols for HRT, peptide therapies, and NAD.
- Weight management programs – enhancing GLP-1 and metabolic health solutions with precision treatment plans.
- Preventative care and wellness – integrating with at-home testing kits to provide insights on nutrition, supplementation, and lifestyle recommendations.
Integration Pathway
Through the VSDHOne platform, Hydreight plans to first integrate and scale the AI-driven assistant across its growing ecosystem of providers, pharmacies, and technology partners. VSDHOne serves as the Company’s modular backbone, enabling new technologies to be deployed nationally and licensed to third parties. Over time, Hydreight believes this AI capability can be extended across its three core verticals, creating a unified data and intelligence layer for personalized healthcare delivery.
Market Opportunity
The opportunity for AI-powered clinical assistants extends well beyond IV therapy.
- Healthcare AI & Clinical Decision Support
The global AI in healthcare market was valued at approximately US $26.7 billion in 2024 and is expected to reach US $187 billion by 2030, representing a CAGR of nearly 38% (Grand View Research, The Research Insights). More aggressive projections estimate the market could exceed US $500–700 billion by 2032–2034 (Fortune Business Insights, Market.us). Clinical decision support systems—like the AI assistant Hydreight is integrating into VSDHOne—are among the fastest-growing use cases.
- Wellness & Personalized Care
Adjacent markets such as IV hydration therapy, hormone and longevity treatments, and weight management programs represent significant opportunities on their own. For example, the global IV hydration therapy market was valued at US $2.64 billion in 2024 and is projected to reach US $4.23 billion by 2030, growing at a CAGR of ~8% (Grand View Research). Similarly, the broader intravenous therapy and vein access market is expected to grow from US $54.4 billion in 2023 to US $74.4 billion by 2029 (BCC Research).
By embedding this AI assistant into VSDHOne, Hydreight positions itself to serve both sides of the opportunity: the explosive growth of AI in healthcare and the ongoing demand for personalized wellness solutions.
Jason Drohn, CEO of Auxano, said: “Hydreight is becoming a true all-in-one turnkey solution in this industry, and we are very excited to join forces with them, be part of their ecosystem, and support both their customers and patients.”
Details of the Transaction
The LOI contemplates that the parties will draft, finalize and execute a definitive agreement (a “Definitive Agreement”,) respecting the Transaction on or before November 4, 2025 (the “Outside Date”), with the option to mutually extend the Outside Date by an additional 30 days. The Transaction and the entering into of the Definitive Agreement are subject to mutual due diligence investigations. No finder’s fee will be paid in connection with the Transaction. The completion of the Transaction is subject to the fulfillment or waiver of several conditions, including receipt by Hydreight of approval from the TSX Venture Exchange, if required. The Transaction is expected to be structured as an “Expedited Acquisition” under the policies of the Exchange.
The Company Shares to be issued to Auxano in connection with the Transaction will be issued at a deemed price equal to the greater of CAD $4.20 per share and the lowest price permitted by the policies of the Exchange and will be issued under prospectus exemptions pursuant to National Instrument 45-106 – Prospectus Exemptions of the Canadian Securities Administrators and in reliance upon exemptions from U.S. federal and state registration requirements and will be subject to a statutory hold period of four months in accordance with applicable Canadian securities laws and other hold periods in accordance with applicable U.S. securities laws and may bear legends to this effect.
The securities of the Company have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an available exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there by any sale of the securities referenced in this press release, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Read More: Developing Sales Leaders in 2025 – Top Recommendations to Meet Changing Selling Cycles
